Carboplatin

SEP 11, 2026 · PHASE 3 TRIAL

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

ClinicalTrials.gov

This is a Phase 3 registry record with no posted results; the study is actively enrolling and design facts only can be assessed.

SEP 11, 2026 · PHASE 2 TRIAL

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registration with no results reported; it describes a planned study of an investigational drug in combination therapy for extensive-stage SCLC, addressing dose optimization and safety.

SEP 10, 2026 · PHASE 3 TRIAL

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

ClinicalTrials.gov

Phase 3 trial registration with no results posted; describes planned enrollment and design only, supporting no current evidence of efficacy or safety.

SEP 9, 2026 · PHASE 3 TRIAL

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is an active clinical trial registry record with no posted results; the study design and planned endpoints are documented but outcome data are not yet reported.

SEP 9, 2026 · PHASE 3 TRIAL

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record for an active Phase 3 study with no results posted; the record describes planned design and enrollment only.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 3 study with no results reported; it documents study design and enrollment targets only.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a clinical trial registry record describing a Phase 3 study that is currently recruiting with no results posted; it documents planned design and endpoints only.